FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.225,48 +139,68 (+0,37%) Nasdaq
15.916,61 +304,85 (+1,95%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,87 +0,30 (+0,36%) Bitcoin EUR
59.402,81 -592,27 (-0,99%)
Mesoblast Limited (MSB.AX)
| Chiusura precedente | 0,9150 |
| Aperto | 0,9250 |
| Denaro | 0,9750 x 1092600 |
| Lettera | 0,9300 x 5097500 |
| Min-Max giorno | 0,8900 - 0,9500 |
| Intervallo di 52 settimane | 0,2550 - 1,3511 |
| Volume | |
| Media Volume | 9.875.864 |
| Capitalizzazione | 1,061B |
| Beta (5 anni mensile) | 2,59 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1300 |
| Prossima data utili | 29 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,60 |
GlobeNewswireJane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee. Ms Bell joined the Board in August 2022, and is a banking and finance lawyer with 30 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Austral
- GlobeNewswire
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the treatment of pediatric and adult steroid-refractory acute graft versus host disease (SR-aGVHD), following a Type A meeting held with the United States Food and Drug Administration (FDA). FDA clarified that the key remaining issue for pedi
- GlobeNewswire
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: “We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric
